<DOC>
	<DOCNO>NCT00292266</DOCNO>
	<brief_summary>This open-label , randomize , multicenter , comparative , parallel-group study compare therapeutic effect two interferon-beta-1a regimen relapsing-remitting multiple sclerosis ( MS ) . The primary objective demonstrate superiority Rebif® 44 microgram ( mcg ) subcutaneous injection give three time week ( 132 mcg per week ) Avonex® 30 mcg intramuscular injection give week .</brief_summary>
	<brief_title>A Study Rebif® Compared With Avonex® Treatment Relapsing-remitting Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Age 18 55 year Clinically definite laboratorysupported definite relapsingremitting MS accord Poser 's criterion Two relapse within precede 24 month Clinical stability improve neurological state 4 week Study Day 1 Expanded disability status scale ( EDSS ) score 0 5.5 , inclusive Two lesion consistent MS Screening proton density/T2magnetic resonance imaging ( MRI ) scan perform 28 plus/minus ( +/ ) 4 day Study Day 1 MRI Willingness ability comply protocol duration study Written inform consent give studyrelated procedure part subject 's normal medical care , understand subject withdraw consent time without prejudice future medical care For female subject , lack childbearing potential must satisfy either postmenopausal surgically sterilize use hormonal contraceptive , intrauterine device , diaphragm spermicide condom spermicide duration study . Subjects neither pregnant breastfeeding ; confirmation subject pregnant establish negative serum human chorionic gonadotropin ( hCG ) pregnancy test within 7 day Study Day 1 ( pregnancy test require subject postmenopausal surgically sterilize ) Secondary progressive MS , primary progressive MS progressive relapse MS Prior use interferon Treatment oral systemic corticosteroid adrenocorticotropic hormone ( ACTH ) within 4 week Study Day 1 within 7 day Screening MRI Psychiatric disorder unstable preclude safe participation study Significant leucopenia ( white blood cell count le 0.5 time low limit normal ) within 7 day Study Day 1 Elevated liver function test ( Alanine transaminase [ ALT ] , Aspartate transaminase [ AST ] , alkaline phosphatase total bilirubin great 2 time upper limit normal ) within 7 day Study Day 1 Prior cytokine anticytokine therapy glatiramer acetate within 3 month Study Day 1 Immunomodulatory immunosuppressive therapy within 12 month Study Day 1 , include limited cyclophosphamide , cyclosporin , methotrexate , azathioprine , linomide mitoxantrone Previous use cladribine total lymphoid irradiation Allergy human serum albumin , mannitol gadolinium diethylenetriaminepentacetic acid ( DTPA ) Intravenous immunoglobulin investigational drug procedure 6 month Study Day 1 Systemic disease interfere subject safety , compliance evaluation condition study , insulindependent diabetes , Lyme disease , clinically significant cardiac disease infection human immunodeficiency virus ( HIV ) Human Tcell lymphotrophic virus , Type1 ( HTLV1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Relapsing-remitting Multiple Sclerosis</keyword>
	<keyword>Rebif®</keyword>
	<keyword>Avonex®</keyword>
	<keyword>interferon-beta-1a</keyword>
</DOC>